We create high-quality medicines and make them accessible to people who need them. Global experts with a local presence, we think creatively and act practically. We develop innovative solutions that transform people’s lives, for a healthier world wherever we are.

Messages from the Board


4702.
quotemark graphic

Our strategy is delivering results. Hikma achieved a robust financial performance in 2019 and we are investing in the future to drive sustainable long-term growth and create continued value for shareholders."

Said Darwazah Executive Chairman
4703.
quotemark graphic

2019 was another very good year for Hikma. I am proud of what our teams have achieved, enabling us to provide high-quality medicines to the people that need them."

Sigurdur Olafsson Chief Executive Officer

Five reasons to invest in Hikma

We have a track record of creating value for our shareholders. By focusing on our strategic priorities and leveraging our strengths, we can build upon our success.

  

Our business model


Our business model enables us to respond to the many opportunities and challenges we face.

Our strategy


By focusing on our strategy, we will deliver sustainable growth over the long-term.

Our operations

Our Injectables business develops and manufactures generic injectable products. Our products are sold globally and are primarily used in hospitals.

Core revenue ($m)


40% of Group revenue (2018: 40%)

Our Generics business develops and manufactures oral and other non-injectable generic products. Our products are sold in the US retail market.

Revenue ($m)


33% of Group revenue (2018: 33%)

Our Branded business develops and manufactures branded generics and markets and sells in-licensed patented products in MENA. Our products are sold in the retail and hospital markets.

Revenue ($m)


26% of Group revenue (2018: 26%)